跳至主要内容
临床试验/NL-OMON47227
NL-OMON47227
已完成
不适用

Repeated Controlled Human Hookworm Infection in Healthy Dutch Volunteers - ReCHHI1

eids Universitair Medisch Centrum0 个研究点目标入组 24 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Hookworm infection
发起方
eids Universitair Medisch Centrum
入组人数
24
状态
已完成
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
2018年9月4日
最后更新
2年前
研究类型
Interventional

研究者

入排标准

入选标准

  • 1\. Subject is aged \* 18 and \* 45 years and in good health.
  • 2\. Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
  • 3\. Subject is able to communicate well with the investigator, is available to attend all study visits.
  • 4\. Subject agrees to refrain from blood donation to Sanquin or for other purposes throughout the study period.
  • 5\. For female subjects: subject agrees to use adequate contraception and not to breastfeed for the duration of study.
  • 6\. Subject has signed informed consent.

排除标准

  • 1\. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune\-deficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following:
  • \* Body Mass Index (BMI) \<18\.0 or \>35\.0 kg/m2 at screening;
  • \* positive HIV, HBV or HCV screening tests;
  • \* the use of immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti\-histamines exempted) or expected use of such during the study period;
  • \* Having one of the following laboratory abnormalities: ferritine \<10ug/L, transferrine \<2\.04g/L or Hb \<7\.0 mmol/L for females or \<8\.0 mmol/L for males.
  • \* history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years;
  • \* any history of treatment for severe psychiatric disease by a psychiatrist in the past year;
  • \* history of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset.
  • 2\. Known hypersensitivity to or contra\-indications for use of albendazole. Including co\-medication known to interact with albendazole metabolism (e.g. carbamazepine, phenobarbital, phenytoin, cimetidine, theophylline, dexamethasone)
  • 3\. Known allergy to amphotericin B or gentamicin.

结局指标

主要结局

未指定

相似试验